Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: Evidence from a xenograft study

Hans J. Hammers, Henk M. Verheul, Brenda Salumbides, Rajni Sharma, Michelle Rudek-Renaut, Janneke Jaspers, Preeti Shah, Leigh Ellis, Li Shen, Silvia Paesante, Karl Dykema, Kyle Furge, Bin T. Teh, George Netto, Roberto Pili

Research output: Contribution to journalArticle

Abstract

Tyrosine kinase inhibitors (TKI) targeting angiogenesis via inhibition of the vascular endothelial growth factor pathway have changed the medical management of metastatic renal cell carcinoma. Although treatment with TKIs has shown clinical benefit, these drugs will eventually fail patients. The potential mechanisms of resistance to TKIs are poorly understood. To address this question, we obtained an excisional biopsy of a skin metastasis from a patient with clear cell renal carcinoma who initially had a response to sunitinib and eventually progressed with therapy. Tumor pieces were grafted s.c. in athymic nude mice. Established xenografts were treated with sunitinib. Tumor size, microvascular density, and pericyte coverage were determined. Plasma as well as tissue levels for sunitinib were assessed. A tumor-derived cell line was established and assessed in vitro for potential direct antitumor effects of sunitinib. To our surprise, xenografts from the patient who progressed on sunitinib regained sensitivity to the drug. At a dose of 40 mg/kg, sunitinib caused regression of the subcutaneous tumors. Histology showed a marked reduction in microvascular density and pericyte dysfunction. More interestingly, histologic examination of the original skin metastasis revealed evidence of epithelial to mesenchymal transition, whereas the xenografts showed reversion to the clear cell phenotype. In vitro studies showed no inhibitory effect on tumor cell growth at pharmacologically relevant concentrations. In conclusion, the histologic examination in this xenograft study suggests that reversible epithelial to mesenchymal transition may be associated with acquired tumor resistance to TKIs in patients with clear cell renal carcinoma.

Original languageEnglish (US)
Pages (from-to)1525-1535
Number of pages11
JournalMolecular Cancer Therapeutics
Volume9
Issue number6
DOIs
StatePublished - Jun 2010

Fingerprint

Epithelial-Mesenchymal Transition
Renal Cell Carcinoma
Heterografts
Pericytes
Neoplasms
Nude Mice
Neoplasm Metastasis
Skin
Angiogenesis Inhibitors
Tumor Cell Line
Pharmaceutical Preparations
Protein-Tyrosine Kinases
Vascular Endothelial Growth Factor A
sunitinib
Histology
Phenotype
Biopsy
Therapeutics
Growth

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma : Evidence from a xenograft study. / Hammers, Hans J.; Verheul, Henk M.; Salumbides, Brenda; Sharma, Rajni; Rudek-Renaut, Michelle; Jaspers, Janneke; Shah, Preeti; Ellis, Leigh; Shen, Li; Paesante, Silvia; Dykema, Karl; Furge, Kyle; Teh, Bin T.; Netto, George; Pili, Roberto.

In: Molecular Cancer Therapeutics, Vol. 9, No. 6, 06.2010, p. 1525-1535.

Research output: Contribution to journalArticle

Hammers, HJ, Verheul, HM, Salumbides, B, Sharma, R, Rudek-Renaut, M, Jaspers, J, Shah, P, Ellis, L, Shen, L, Paesante, S, Dykema, K, Furge, K, Teh, BT, Netto, G & Pili, R 2010, 'Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: Evidence from a xenograft study', Molecular Cancer Therapeutics, vol. 9, no. 6, pp. 1525-1535. https://doi.org/10.1158/1535-7163.MCT-09-1106
Hammers, Hans J. ; Verheul, Henk M. ; Salumbides, Brenda ; Sharma, Rajni ; Rudek-Renaut, Michelle ; Jaspers, Janneke ; Shah, Preeti ; Ellis, Leigh ; Shen, Li ; Paesante, Silvia ; Dykema, Karl ; Furge, Kyle ; Teh, Bin T. ; Netto, George ; Pili, Roberto. / Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma : Evidence from a xenograft study. In: Molecular Cancer Therapeutics. 2010 ; Vol. 9, No. 6. pp. 1525-1535.
@article{713ab0a7124344dfb279e827aab08b3b,
title = "Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: Evidence from a xenograft study",
abstract = "Tyrosine kinase inhibitors (TKI) targeting angiogenesis via inhibition of the vascular endothelial growth factor pathway have changed the medical management of metastatic renal cell carcinoma. Although treatment with TKIs has shown clinical benefit, these drugs will eventually fail patients. The potential mechanisms of resistance to TKIs are poorly understood. To address this question, we obtained an excisional biopsy of a skin metastasis from a patient with clear cell renal carcinoma who initially had a response to sunitinib and eventually progressed with therapy. Tumor pieces were grafted s.c. in athymic nude mice. Established xenografts were treated with sunitinib. Tumor size, microvascular density, and pericyte coverage were determined. Plasma as well as tissue levels for sunitinib were assessed. A tumor-derived cell line was established and assessed in vitro for potential direct antitumor effects of sunitinib. To our surprise, xenografts from the patient who progressed on sunitinib regained sensitivity to the drug. At a dose of 40 mg/kg, sunitinib caused regression of the subcutaneous tumors. Histology showed a marked reduction in microvascular density and pericyte dysfunction. More interestingly, histologic examination of the original skin metastasis revealed evidence of epithelial to mesenchymal transition, whereas the xenografts showed reversion to the clear cell phenotype. In vitro studies showed no inhibitory effect on tumor cell growth at pharmacologically relevant concentrations. In conclusion, the histologic examination in this xenograft study suggests that reversible epithelial to mesenchymal transition may be associated with acquired tumor resistance to TKIs in patients with clear cell renal carcinoma.",
author = "Hammers, {Hans J.} and Verheul, {Henk M.} and Brenda Salumbides and Rajni Sharma and Michelle Rudek-Renaut and Janneke Jaspers and Preeti Shah and Leigh Ellis and Li Shen and Silvia Paesante and Karl Dykema and Kyle Furge and Teh, {Bin T.} and George Netto and Roberto Pili",
year = "2010",
month = "6",
doi = "10.1158/1535-7163.MCT-09-1106",
language = "English (US)",
volume = "9",
pages = "1525--1535",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma

T2 - Evidence from a xenograft study

AU - Hammers, Hans J.

AU - Verheul, Henk M.

AU - Salumbides, Brenda

AU - Sharma, Rajni

AU - Rudek-Renaut, Michelle

AU - Jaspers, Janneke

AU - Shah, Preeti

AU - Ellis, Leigh

AU - Shen, Li

AU - Paesante, Silvia

AU - Dykema, Karl

AU - Furge, Kyle

AU - Teh, Bin T.

AU - Netto, George

AU - Pili, Roberto

PY - 2010/6

Y1 - 2010/6

N2 - Tyrosine kinase inhibitors (TKI) targeting angiogenesis via inhibition of the vascular endothelial growth factor pathway have changed the medical management of metastatic renal cell carcinoma. Although treatment with TKIs has shown clinical benefit, these drugs will eventually fail patients. The potential mechanisms of resistance to TKIs are poorly understood. To address this question, we obtained an excisional biopsy of a skin metastasis from a patient with clear cell renal carcinoma who initially had a response to sunitinib and eventually progressed with therapy. Tumor pieces were grafted s.c. in athymic nude mice. Established xenografts were treated with sunitinib. Tumor size, microvascular density, and pericyte coverage were determined. Plasma as well as tissue levels for sunitinib were assessed. A tumor-derived cell line was established and assessed in vitro for potential direct antitumor effects of sunitinib. To our surprise, xenografts from the patient who progressed on sunitinib regained sensitivity to the drug. At a dose of 40 mg/kg, sunitinib caused regression of the subcutaneous tumors. Histology showed a marked reduction in microvascular density and pericyte dysfunction. More interestingly, histologic examination of the original skin metastasis revealed evidence of epithelial to mesenchymal transition, whereas the xenografts showed reversion to the clear cell phenotype. In vitro studies showed no inhibitory effect on tumor cell growth at pharmacologically relevant concentrations. In conclusion, the histologic examination in this xenograft study suggests that reversible epithelial to mesenchymal transition may be associated with acquired tumor resistance to TKIs in patients with clear cell renal carcinoma.

AB - Tyrosine kinase inhibitors (TKI) targeting angiogenesis via inhibition of the vascular endothelial growth factor pathway have changed the medical management of metastatic renal cell carcinoma. Although treatment with TKIs has shown clinical benefit, these drugs will eventually fail patients. The potential mechanisms of resistance to TKIs are poorly understood. To address this question, we obtained an excisional biopsy of a skin metastasis from a patient with clear cell renal carcinoma who initially had a response to sunitinib and eventually progressed with therapy. Tumor pieces were grafted s.c. in athymic nude mice. Established xenografts were treated with sunitinib. Tumor size, microvascular density, and pericyte coverage were determined. Plasma as well as tissue levels for sunitinib were assessed. A tumor-derived cell line was established and assessed in vitro for potential direct antitumor effects of sunitinib. To our surprise, xenografts from the patient who progressed on sunitinib regained sensitivity to the drug. At a dose of 40 mg/kg, sunitinib caused regression of the subcutaneous tumors. Histology showed a marked reduction in microvascular density and pericyte dysfunction. More interestingly, histologic examination of the original skin metastasis revealed evidence of epithelial to mesenchymal transition, whereas the xenografts showed reversion to the clear cell phenotype. In vitro studies showed no inhibitory effect on tumor cell growth at pharmacologically relevant concentrations. In conclusion, the histologic examination in this xenograft study suggests that reversible epithelial to mesenchymal transition may be associated with acquired tumor resistance to TKIs in patients with clear cell renal carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=77953467629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953467629&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-09-1106

DO - 10.1158/1535-7163.MCT-09-1106

M3 - Article

C2 - 20501804

AN - SCOPUS:77953467629

VL - 9

SP - 1525

EP - 1535

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 6

ER -